177Lu-PSMA-617 radioligand therapy ([RLT] which is regarded as the mainstay 177Lu-labeled PSMA agent in this review) has demonstrated its ability to target prostate cancer cells while sparing most normal tissues in patients that have been identified using imaging to confirm radionuclide binding with the prostate cancer cells [7]. This evidence concerns the gene FOLH1 and prostate carcinoma.